Spyre Therapeutics (SYRE) Other Gross PP&E Adjustments (2015 - 2025)

Spyre Therapeutics has reported Other Gross PP&E Adjustments for 11 years, with the latest figure at -$12.9 million in Q4 2025.

• For the quarter ending Q4 2025, Other Gross PP&E Adjustments fell 81.94% year-over-year to -$12.9 million; the trailing twelve-month figure through Mar 2026 stood at -$12.9 million (down 81.94% YoY), and the FY2025 full-year result was -$12.9 million, down 81.94% from the prior year.
• Other Gross PP&E Adjustments for Q4 2025 stood at -$12.9 million, down from -$7.1 million in the prior quarter.
• The five-year high for Other Gross PP&E Adjustments was $778000.0 in Q4 2021, with the low at -$12.9 million in Q4 2025.
• Historically, Other Gross PP&E Adjustments has averaged -$5.0 million across 5 years, with a median of -$5.3 million in 2021.
• The largest YoY upside for Other Gross PP&E Adjustments was 34.28% in 2023 against a maximum downside of 762.4% in 2023.
• Spyre Therapeutics' Other Gross PP&E Adjustments stood at $778000.0 in 2021, then decreased by 17.61% to $641000.0 in 2022, then plunged by 762.4% to -$4.2 million in 2023, then sank by 67.55% to -$7.1 million in 2024, then tumbled by 81.94% to -$12.9 million in 2025.
• The last three Other Gross PP&E Adjustments figures came in at -$12.9 million (Q4 2025), -$7.1 million (Q4 2024), and -$4.2 million (Q4 2023), per Business Quant data.